Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- S-4/A Registration of securities issued in business combination transactions
- 5.1 Opinion of Ropes & Gray LLP
- 23.1 Consent of Ernst & Young LLP
- 23.2 Consent of Ernst & Young LLP
- 23.4 Consent of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP
- 23.5 Consent of Harris Nesbitt Corp.
- 99.4 Consent of Merrill Lynch, Pierce, Fenner & Smith Incorporated
- 99.5 Form of Genome Therapeutics Corp. Proxy Card
- 99.6 Form of Genesoft Pharmaceuticals, Inc. Proxy Card
- 99.9 Consent of David B. Singer
- 99.10 Consent of Luke B. Evnin
- 99.11 Consent of William J. Rutter
- 99.12 Consent of Vernon R. Loucks, JR.
OSCI similar filings
- 10 Sep 08 Registration of securities issued in business combination transactions
- 15 Mar 07 Registration of securities issued in business combination transactions
- 30 Dec 03 Registration of securities issued in business combination transactions (amended)
- 15 Dec 03 Registration of securities issued in business combination transactions
Filing view
External links
Exhibit 99.10
CONSENT
The undersigned, who has agreed to serve as a member of the Board of Directors of Genome Therapeutics Corp. (the “Company”) following the completion of the merger between Genesoft Pharmaceuticals, Inc. and Guardian Acquisition, Inc., a wholly-owned subsidiary of the Company, hereby grants the Company consent to use his name in its Registration Statement on Form S-4 and all amendments, including post-effective amendments, to the Registration Statement (or any other Registration Statement for the same offering that is to be effective upon filing pursuant to Rule 462(b) under the Securities Act of 1933).
Dated: December 29, 2003
/s/ Luke B. Evnin
Luke B. Evnin